Physicians: Access OS Data For An Extensive-Stage Small Cell Lung Cancer Therapy.
Providing Same or Next Day Access to Cancer Diagnostic Services from the Cancer Experts.
We asked top doctors to explain when immunotherapy can be used and its potential benefits.
Examine the Consequences Current Treatments Have on mNSCLC Patients. Find Out More.
SEER stage | 5-year relative survival rate |
Localized | 30% |
Regional | 18% |
Distant | 3% |
All SEER stages combined | 7% |
People also ask
What is the life expectancy for someone with small cell lung cancer?
Has anyone ever beaten stage 4 lung cancer?
Is small cell lung cancer considered terminal?
How aggressive is small cell lung cancer?
The 5-year survival rate was 3.5% (limited-stage disease, 4.8%; extensive-stage disease, 2.3%), and the 10-year survival rate was 1.8% (limited-stage disease, ...
Most lung cancer statistics include both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In general, about 10% to 15% of all lung cancers ...
Feb 6, 2023 · The overall prognosis for patients with SCLC is poor, with a median overall survival (OS) of 15–20 months for LD-SCLC and 8–13 months for ED- ...
Lung Cancer - Small Cell - Statistics - Human Verification
www.cancer.net › cancer-types › statistics
JavaScript is disabled. In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Nov 4, 2023 · Survival Rates by Stages · Stage IA1: 97% (2 years); 90% (5 years) · Stage IA2: 94%; 85% · Stage IA3: 92%; 80% · Stage IB: 89%; 73% · Stage IIA: 82%; ...
May 23, 2024 · In This Section ... Chemotherapy and radiation therapy have been shown to improve survival for patients with small cell lung cancer (SCLC).
View Our Blog, Podcasts & Webinars for More Information on LUNGevity's Resources. Visit Our Lung Cancer 101 Guide for a Comprehensive Look at Lung Cancer Stages.
People also search for
Related health topics
For informational purposes only. Consult your local medical authority for advice.